Shareholder Information

Overview

MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The Company’s tests are based on proprietary genetic, epigenetic and other complex molecular technologies.

MDxHealth is dedicated to providing highly accurate and clinically actionable urologic solutions to inform patient diagnosis and treatment while improving healthcare economics for payers and providers.

An overview of the most recent information about MDxHealth can be found in the company’s periodic corporate presentation slides and can be download here.

Corporate Presentation March 2022

MDxHealth is listed on the Euronext and on NASDAQ under the ticker symbol MDXH.

MDxHealth has been listed on Euronext since 2006 and on NASDAQ since 2021. There is only one class of shares in the company (common shares) and all shares have the same rights and voting representation. Other than American Depository Shares (ADS) listed on NASDAQ (each representing ten common shares) and stock options issued to employees, directors, and some consultants, there are no other financial instruments issued by the company.

The company reports its consolidated financial statements under International Financial Reporting Standards (IFRS) and all amounts are in US Dollars. MDxHealth publishes a consolidated and audited Annual Report on an annual basis, a consolidated Interim Report for its June 30 half-year financial figures, and business/financial updates at the end of Q1 and Q3.

Corporate Governance Charter

MDxHealth attaches great value to corporate governance practices. On April 14, 2021, our board of directors approved the current version of MDxHealth’s Corporate Governance Charter. The Charter has been drafted in accordance with the principles of Belgian. Code on Corporate Governance.

MDxHealth’s Corporate Governance Charter can be download here: English

Code of Ethics

MDxHealth’s Code of Ethics can be downloaded here: English

Dealing Code

As a listed company, MDxHealth must comply with rules governing insider trading. The company’s dealing code can be found here: English

Remuneration Policy

MDxHealth’s Remuneration Policy can be found here: English I Français

Articles of Association

The Articles of Association are periodically updated. The latest version can be found here: English IFrançais

Share capital history

The history of the share capital issuance since the inception of the company can be found here:

History of share capital Nov. 2021

Major Shareholders

MDxHealth’s shareholder structure, based on the most recent number of shares and transparency notifications and filings, is as follows:

22.8%	MVM Partners LLP
15.2%	Bleichroeder LP
12.2%	Valiance Asset Management Limited
7.1%	Biovest NV

The Articles of the Association of MDxHealth SA provide for shareholders notification threshold of 3%, 5% or a multiple of 5% (i.e. 10%, 15%, 20% etc) of the total number of existing voting rights. The notification forms can be downloaded from the website of the FSMA. Completed and signed forms should be sent to ir@mdxhealth.com.

Please see transparency press releases and SEC filings for further details.

Ordinary and Extraordinary General Shareholders’ Meetings (May 25, 2022) | Assemblées Générales Ordinaire Et Extraordinaire Des Actionnaires (25 Mai 2022)

Convening Notice (EN) | Invitation (FR)

Attendance Form (EN) | Formulaire de Participation (FR)

Proxy Form (EN) | Formulaire de Procuration (FR)

Voting by mail Form (EN) | Formulaire de Vote par Correspondance (FR)

Outstanding Shares and Voting Rights (EN) | Actions et Droits de Votes en Circulation (FR)

Comptes Annuels Statutaires (non consolidés) (FR)

2021 Annual Report – Consolidated Financial Statements (EN) | Comptes Annuels Consolidés (FR)

Rapport Annuel du Conseil d’Administration sur les Comptes Annuels Statutaires (non consolidés) (FR)

Annual Report of the Board of Directors on the Consolidated Financial Statements (EN) | Rapport Annuel du Conseil d’Administration sur les Comptes Annuels Consolidés (FR)

Report of the Statutory Auditor on the (non-consolidated) Statutory Financial Statements (EN) | Rapport du Commissaire sur les Comptes Annuels Statutaires (non consolidés) (FR)

Report of the Statutory Auditor on the Consolidated Financial Statements (EN) | Rapport du Commissaire sur les Comptes Annuels Consolidés (FR)

Board Report in relation to the 2022 Share Option Plan (EN) | Rapport du Conseil d’Administration sur le Plan d’Option sur Action de 2022 (FR)

Rapport du Commissaire sur le Plan d’Option sur Action de 2022 (FR)

2022 Share Option Plan (EN) | Plan d’Option sur Action de 2022 (FR)